3-ethyl-4-(3-methyl-3H-imidazol-4-ylmethyl)-pyrrolidin-2-one | 46410-38-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-ethyl-4-(3-methyl-3H-imidazol-4-ylmethyl)-pyrrolidin-2-one
• 英文别名: 3-Ethyl-4-[(3-methylimidazol-4-yl)methyl]pyrrolidin-2-one
• CAS: 46410-38-2
• 化学式: C₁₁H₁₇N₃O
• 分子量: 207.275
• InChiKey: LWYKXKGPFMXVIY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  46.9
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• N-substituted derivatives of 3R,4R-ethyl-[(1-methyl-1H-imidazol-5-yl)methyl]-2-pyrrolidinone
  申请人：ALLERGAN, INC.

  公开号：EP0429232A1

  公开（公告）日：1991-05-29

  The present invention relates to new carbonyl 3R,4R-­ethyl-[(1-methyl-1H-imidazol-5-yl)methyl]-2-pyrrolidinone derivatives carrying a carboxyester-type lipophilic moiety on the pyrrolidinone nitrogen. More particularly, the present invention concerns new N-substituted carbonyl-­3R,4R-ethyl-[(1-methyl-1H-imidazol-5-yl)methyl]-2-­pyrrolidinone derivatives of the formula (I): wherein R is an optionally substituted hydrocarbon group, and pharmaceutically acceptable acid addition salts thereof. The new compounds of the formula (I) are potent ocular hypotensives that are valuable antiglaucoma agents. They are also targeted for use in the treatment of so-called dry eye.

  本发明涉及新的羰基-3R,4R-乙基-[(1-甲基-1H-咪唑-5-基)甲基]-2-吡咯烷酮衍生物，其吡咯烷酮氮上带有羧酯型亲脂分子。 更具体地说，本发明涉及式（I）的新的 N-取代羰基-3R,4R-乙基-[(1-甲基-1H-咪唑-5-基)甲基]-2-吡咯烷酮衍生物：其中 R 是任选取代的烃基，以及它们的药学上可接受的酸加成盐。 式（I）的新化合物是有效的降眼压药，是有价值的抗青光眼药物。 它们还可用于治疗所谓的干眼症。
• Novel pharmaceutical epinephrine-pilocarpine derivatives
  申请人：ALLERGAN, INC.

  公开号：EP0432899A1

  公开（公告）日：1991-06-19

  The present invention relates to new racemic and optically active compounds containing a first moiety derived from a pilocarpine compound in which the furanone ring of pilocarpine is replaced by a hetero-ring containing a secondary nitrogen hetero­atom, and a second moiety derived from an epinephrine compound or a β-adrenergic blocking compound, linked at the secondary nitrogen atom of the furanone-replacing hetero-ring of the pilocarpine compound and at the hydroxyl group of the epinephrine compound or of the β-adrenergic blocking compound, via a carbonyl linker, and pharmaceutically acceptable acid addition salts thereof. The new compounds of the present invention are potent ocular hypotensives exhibiting minimal deleterious pupillary effects.

  本发明涉及新的外消旋光学活性化合物，其第一分子来源于皮洛卡品化合物，其中皮洛卡品的呋喃酮环被含有仲氮杂原子的杂环取代；第二分子来源于肾上腺素化合物或β-肾上腺素能阻断化合物、通过羰基连接体连接在皮洛卡品化合物的呋喃酮取代杂环的仲氮原子上和肾上腺素化合物或β-肾上腺素能阻断化合物的羟基上，及其药学上可接受的酸加成盐。 本发明的新化合物是强效的降眼压药，对瞳孔的有害影响极小。
• US5055467A
  申请人：——

  公开号：US5055467A

  公开（公告）日：1991-10-08
• US5198545A
  申请人：——

  公开号：US5198545A

  公开（公告）日：1993-03-30